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Abstract 
 
Background: Ethnicity, along with a variety of genetic and environmental factors, is thought to 
influence the efficacy of anti-hypertensive therapies. Current UK guidelines employ a ‘black vs 
white’ approach; in doing so, they ignore the UK’s largest ethnic minority, Asians from South 
Asia.  
 
Study design: The primary purpose of the AIM-HY INFORM trial is to identify potential 
differences in response to antihypertensive drugs used as mono- or dual-therapy on the basis 
of self-defined ethnicity. A multi-center, prospective, open-label, randomized study with two 
parallel, independent trial arms (mono- and dual-therapy), AIM-HY INFORM plans to enroll a 
total of 1320 patients from across the UK. Those receiving mono-therapy (n=660) will enter a 
three-treatment (Amlodipine 10 mg od; Lisinopril 20 mg od; Chlorthalidone 25 mg od), three-
period crossover, lasting 24 weeks, whilst those receiving dual-therapy (n=660) will enter a 
four-treatment (Amlodipine 5 mg od and Lisinopril 20 mg od; Amlodipine 5 mg od and 
Chlorthalidone 25 mg od; Lisinopril 20 mg od and Chlorthalidone 25 mg od; Amiloride 10 mg 
od and Chlorthalidone 25 mg od), four-period crossover, lasting 32 weeks. Equal numbers of 
three ethnic groups (White, Black/Black British, and Asian/Asian British) will ultimately be 
recruited to each of the trial arms (i.e., 220 participants per ethnic group per arm). Seated, 
automated, unattended, office, systolic blood pressure measured eight weeks after each 
treatment period begins will serve as the primary outcome measure.  
 
Conclusion: AIM-HY INFORM is a prospective, open-label, randomized trial which aims to 
evaluate first and second-line anti-hypertensive therapies for multi-ethnic populations.  
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Introduction 
 
Hypertension is the single biggest contributor to the global burden of disease, a burden that is 
particularly great in lower and middle-income countries (LMIC).1 In high income economies, 
ethnic minorities - often originating from LMICs - also appear to be disproportionately 
affected, when compared to indigenous populations.2-4 Complex interactions between genes 
and the environment are thought to influence the pathophysiology of essential hypertension, 
the frequency of hypertension-related complications, and the response to treatment.1 
However, data relating to ethnicity are complicated by the plethora of methods used to define 
‘ethnicity’ or ‘race’, and a greater understanding of environmental influences has led to the 
recognition that data collected in one country, may not be readily applicable to similar ethnic 
groups in distinct geographical locations.1  
 
European guidelines relating to the management of arterial hypertension make no allowance 
for ethnicity.5 In contrast, the North American guideline, published by the Joint National 
Committee in 2014, does, stating, “In the general black population, including those with 
diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB 
[calcium channel blocker]”.6 Stratified by age and self-defined ethnicity (SDE), the UK’s 
National Institute for Health and Care Excellence (NICE) recommends a third approach, with 
distinct initial mono-therapies recommended for all those aged 55 years and over, as well as 
for younger black adults when compared to whites.7 However, the guideline makes no 
reference to South Asians (i.e. those originating from the Indian sub-continent) - despite the 
fact that they represent the largest ethnic minority group in the UK at 4.7 million people (52.5 
million ‘white British’ citizens being the largest group within a total population of 65.6 million 
people).7,8 Furthermore, the afore-mentioned guidelines fail to extend stratification to 
combination therapy.5-7 
 
Stratification on the basis of self-defined ethnicity is potentially flawed by virtue of an 
increasingly ‘ad-mixed’ population, the complex relationship between ethnicity and phenotype 
and its inherent cohort based approach which fails to account for inter-individual variations.9 
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An alternative method of stratification seeks to utilize ancestry informative markers (AIMs) - 
genetic polymorphisms occurring with substantially different frequencies across populations 
from distinct geographical regions. Able to predict geographical ancestry, AIMs may capture 
the genetic component responsible for variations in drug response amongst ethnically diverse 
populations more discerningly than SDE.9,10 Concurrent metabolomic profiling of plasma and 
urine (measurement of low- and intermediate-molecular weight metabolites which reflect the 
complex inter-play between genetic, physiological, pathophysiological, and/or environmental 
factors) offers the potential to augment AIMs, with differences between individuals reflecting 
the entire spectrum of influences, especially diet.11,12  
 
In an effort to address these issues, the AIM-HY INFORM trial intends to compare variations in 
response to antihypertensive agents amongst three cohorts of the UK population stratified on 
the basis of SDE, whilst also relating any variations to AIMs and metabolomic profiles. In doing 
so, we hope to evaluate the validity of current NICE guidance which has SDE at the center of its 
approach to pharmacotherapy, and to examine whether use of AIMs and/or metabolomic 
profiling results in the more effective personalization of antihypertensive treatment. 
Furthermore, the trial will evaluate the efficacy of both mono-therapy and dual-therapy across 
all three cohorts and try to elucidate potential mechanisms underlying any difference in 
outcomes achieved by using SDE and AIMs. Thus AIM-HY INFORM will enable clinicians to 
optimize their choice of anti-hypertensive treatments from current, generic, first- and second-
line agents, reducing the attrition of antihypertensive therapies.  
 
Hypotheses  
 
We hypothesize that the response to antihypertensive drugs (used either as mono- or dual-
therapy) differs by ethnicity.  
 
Our secondary hypothesis relates to the possibility that ancestry informative markers and 
metabolites, and/or baseline haemodynamic measurements, are able to predict response to 
antihypertensive therapy.  
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 Methods  
 
Study design and objectives  
 
AIM-HY INFORM is a multi-center, prospective, open-label study with two parallel, 
independent trial arms (mono- and dual-therapy). Eleven UK sites will enroll a total of 1320 
patients. Those receiving mono-therapy (n=660) will enter a three-treatment, three-period 
crossover, lasting 24 weeks, whilst those receiving dual-therapy (n=660) will enter a four-
treatment, four-period crossover, lasting 32 weeks. Equal numbers of all three ethnic groups 
(White, Black/Black British, and Asian/Asian British) will ultimately be recruited to each of the 
trial arms (i.e., 220 participants per ethnic group per arm). 
 
The primary objective of the AIM-HY INFORM trial is to determine whether the response to 
antihypertensive drugs differs on the basis of SDE. Secondary objectives (Table 1) include an 
evaluation of this response on the basis of AIMs, baseline metabolomics, baseline 
haemodynamic data, genomics and a more detailed evaluation of SDE (with a family tree 
extending to three generations, i.e., grandparents). Additionally, the trial aims to determine: 1) 
the most effective mono- and dual-therapy for hypertension, and any variation(s) by ethnicity, 
2) whether metabolomics and haemodynamics differ by ethnicity, and 3) whether previously 
identified biomarkers (i.e., those derived from other cohorts e.g. the USA) can predict the 
therapeutic response observed. Further exploratory, tertiary objectives, may be defined.  
 
Study population, treatment assignment and randomization 
 
The inclusion and exclusion criteria are listed in Table II. Hypertensive adults aged between 18 
and 65 years are eligible for inclusion, provided that they are able to self-identify with one of 
the three ethnicities outlined. Treatment-naïve individuals will be confined to the mono-
therapy arm. Those who have previously been treated/are being treated with anti-
hypertensive agents will be able to enter either arm, provided they are able to under-go a 
washout of 2-4 weeks; if not, they will be assigned to dual-therapy.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 10 
 
Following allocation to a trial arm, subjects will be randomized to a sequence of drugs (Figure 
1) using an online system (https://www.sealedenvelope.com). This requires the participant 
screening number, initials, date of birth, and self-defined ethnicity, along with the site name, 
confirmation of eligibility and trial arm allocation. For those receiving mono-therapy, six 
possible treatment sequences may be generated, as the intervention consists of a three-
treatment, three-period crossover; ABC, ACB, BAC, BCA, CAB, and CBA. Where subjects are 
allocated dual-therapy (a four-treatment, four-period crossover), four possible treatment 
sequences exist; ABDC, BCAD, CDBA, and DACB. In both instances a Latin square, balanced for 
first order carryover effects is deployed;13 the randomization schedule will also aim to have 
equal numbers of participants in each sequence.  
 
Prescribed in an open-label manner, the treatments allocated to each letter are detailed in 
Table III. Stable concomitant therapy for unrelated indications is permitted provided it does 
not have an anti-hypertensive effect; dose modifications for the trial drugs are not permitted. 
As this is a pragmatic trial of licenced medications, overall adherence will be assessed by urine 
drug screening for the study medications in a randomly selected subgroup of individuals 
(n=50). Participants will also be asked to self-report on compliance; where this falls below 75%, 
subjects may be withdrawn as the discretion of the principal/chief investigator(s).  
 
Outcome measures 
 
The primary outcome measure is seated, office, unattended systolic blood pressure measured 
eight weeks after each treatment period begins. A validated, automated, brachial blood 
pressure machine – the Omron® HEM-907 - will be used to record three serial measurements. 
 
Secondary and tertiary outcome measures are shown in Table IV. Analysis of potential genetic 
polymorphisms associated with response to anti-hypertensive treatment will be limited to 
those polymorphisms previously linked to blood pressure via genome-wide association 
studies.14 Preliminary retrospective analyses of randomised controlled trials evaluating the 
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efficacy of anti-hypertensive drugs suggest that many of these variants are also linked to anti-
hypertensive drug response with relatively large effect size; such effects may arise as a result 
of an overlap between the homeostatic pathways mediating blood pressure control and drug 
targets.  Additionally, genomic variants known to be specifically associated with anti-
hypertensive drug response, published prior to the time of analysis, will be evaluated.15 This 
will maximise the power of our trial to detect genetic associations, whilst avoiding the 
limitations of a candidate gene approach. The association with metabolites will be exploratory, 
utilising a "metabolite-wide" association study (MWAS) approach, whilst also revisiting 
metabolites that have previously been deemed significant in published metabolite-wide 
association studies at the time of analysis.16,17 
 
Sample size calculation  
 
In order to identify the effect of ethnicity upon response to the various treatment options 
trialed with 98% power, 200 patients from each of the three ethnic groups, i.e. 600 subjects 
per trial arm, will be required. This assumes a SD for daytime systolic BP of 8 mmHg, use of a 
global test of interaction at the 5% significance level and a single interaction of 4 mmHg with 
others of 0 mmHg. Should the single interaction be 3 mmHg, the power is reduced to 81.3%. 
However, 4 mmHg is an effect size approximately 50% of that reported for some of the agents 
to be used in this trial, when studied amongst black and white participants in the USA.18  
 
To allow for a 10% dropout rate, the trial will enroll 660 participants per trial arm, with 220 
subjects from each of the three ethnic groups. Recruitment for each ethnic group will cease 
when 220 participants are enrolled, to ensure equal numbers of patients are recruited. 
Subgroup assessments are not powered as these are exploratory measures. 
 
Statistical methods  
 
The two crossover trials will be considered distinct entities for analytical purposes; the results 
will be interpreted separately, on an intention-to-treat basis. The primary endpoint – 
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automated, office, systolic blood pressure - will be analyzed using a linear mixed effects model. 
This endpoint will serve as the dependent variable, participant ID the random effect, with 
treatment factors, treatment period, ethnic group and treatment by ethnic group the fixed 
effects. The global test of interaction, at a 5% significance level, will be used to determine 
whether the treatment effect varies with ethnicity. In the event of a significant global test, the 
efficacy of individual agents/treatments will be estimated with nominal 95% confidence 
intervals; the assumptions of the model will be assessed using graphical methods e.g., a Q-Q 
plot, plots of residual versus fitted values, etc. If any of the assumptions are violated, the 
dependent variable may be transformed to a normal distribution; if this fails to correct the 
distributional assumptions, non-parametric methods will be used.  
 
Analysis of secondary and tertiary outcomes will be dependent upon the volume of data 
acquired; assessments of this (and the appropriate statistical methods) will be determined by 
the independent chair of the Trial Steering Committee (see below). A detailed statistical 
analysis plan will be produced before the database is locked and/or before any interim analysis 
is performed.  
 
Interim analysis and sample size reassessment  
 
With limited prior data describing intra-individual standard deviations in SBP, the multilevel 
nature of the trial design mandates an interim sample size re-estimation. Statistically robust 
and confined to an analysis of SD in BP, this will be undertaken for each trial arm (mono-
therapy and dual-therapy) after approximately 50 participants have completed at least two 
treatment periods. Given the likelihood that recruitment to the two arms will differ, it is 
anticipated that the sample size re-estimations are unlikely to occur simultaneously.  
 
Only results of the sample size re-estimation will be communicated to investigators; the details 
of any treatment effects will not be made available.  
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 13 
Organization and funding  
 
The trial, sponsored by Cambridge University Hospitals NHS Foundation Trust and the 
University of Cambridge, is led by the Cambridge Clinical Trials Unit at Cambridge University 
Hospitals NHS Foundation Trust. Addenbrooke’s Hospital, Cambridge serves as the 
coordinating center, whilst the Cambridge South (East of England) Research Ethics Committee 
provided a favourable ethical opinion for the protocol in October 2016.  
 
A Trial Steering Committee (TSC) consisting of experienced clinical investigators provides 
overall supervision for the trial, ensuring that it is conducted in accordance with the protocol 
and Good Clinical Practice. Convening at regular intervals and independently chaired 
(Professor Peter Sever), the committee assumes overall responsibility for participant safety, 
consideration of new information and reviewing data, as specified in the TSC charter 
 
Part of the wider AIM-HY consortium, the AIM-HY INFORM trial is funded by the Medical 
Research Council (MRC) and British Heart Foundation (BHF). The sponsors and funding 
organizations have no role in the study design, study management, or data interpretation. The 
investigators (authors) alone are responsible for these aspects of the study, as well as any data 
analysis, the drafting and editing of manuscripts, and their final contents. 
 
Current status  
 
At present eight investigation centers are actively recruiting patients and it is anticipated that 
the trial will be completed by mid-late 2020; the results reported approximately six-nine 
months later. The first patient was consented on 20 February 2017 and randomized on 6 
March 2017; as of 15 May 2018, 318 patients had been consented, with 252 randomized. The 
study has been registered with the website ClinicalTrials.gov (NCT02847338). 
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Commentary 
 
Ethnicity influences blood pressure status, both at an individual and population level; 
epidemiological data from the US demonstrate a greater prevalence of hypertension amongst 
African-Americans, along with poorer blood pressure control amongst this cohort of the 
population.19-22 However, data describing the prevalence of hypertension amongst the UK’s 
various ethnic groups is inconsistent. Some UK studies describe a greater prevalence of 
hypertension, and significantly higher mean blood pressure, in both Afro-Caribbean and South 
Asian populations when compared to the indigenous white population.23,24 Other studies have 
shown significant variations in blood pressure data amongst sub-groups of the South Asian 
population with some sections of this community reportedly having lower BP readings than 
white adults; at various times, these differences have been attributed to religion (e.g., Muslim, 
Sikh, Hindu, etc.,), nation of origin (e.g., India, Pakistan, Bangladesh, etc.,) and cultural 
grouping (e.g., Gujarati, Punjabi, etc.,).25-27 Furthermore, studies which consider admixed 
populations are sparse, despite the fact that this cohort of the population is growing in size; 
over one million people in the UK identify as ‘mixed’, with 0.8% of the English and Welsh 
population describing themselves as being ‘White-Black Caribbean’, 0.6% ‘White-Asian’, 0.3% 
‘White-Black African’ and 0.5% ‘Other Mixed’.8 
 
The pathophysiology of hypertension also appears to vary between ethnic groups. In the UK 
South Asian population, elevated sympathetic activity, arising from an increased prevalence of 
central obesity and insulin resistance, is believed to be causally related to blood pressure, 
whilst ‘low-renin’ hypertension is commonly described amongst black adults, with the 
resulting salt and water retention a significant determinant of blood pressure status.28-32 In 
contrast, salt-sensitive hypertension is relatively infrequent in white adults.31,32 Black patients 
are also reported to express variants of several genes, most frequently a threonine to 
methionine substitution, T594M, affecting the renal tubular absorption of sodium and water.33 
Phenotypically akin to Liddle’s syndrome, this pathophysiological mechanism is primarily 
mediated via the renal tubular epithelial sodium channel.34  
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Treatment on the basis of these observations has resulted in the use of diuretics in 
hypertensive adults with low plasma renin activity, and antagonists of the renin-angiotensin 
axis (e.g. angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor blockers 
(ARBs) or beta-blockers) in individuals with higher plasma renin activity.35-38 In addition to this, 
the parallels to Liddle’s syndrome have led a number of authors to advocate the use of 
amiloride amongst cohorts of black patients, both in the UK and elsewhere, whilst the elevated 
sympathetic activity observed amongst South Asians has been used to justify ACEi, ARB and 
beta-blocker use in this group.28,39  
 
Although data relating to Asians in the North American literature is limited – and where it is 
available ‘Asian’ frequently equates to ‘Far Eastern’ (Chinese, Japanese, etc.,)40,41 - results from 
several, large US studies provide some evidence of ethnic variation in response to 
antihypertensive drugs34,42-47 In broad terms, greater falls in blood pressure are achieved with 
thiazide/thiazide-like diuretics in black subjects with hypertension when compared to their 
white peers; conversely, ACEi are less effective in this cohort. In the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), patients on chlorthalidone 
achieved better BP control than those receiving lisinopril or amlodipine. Those using lisinopril 
had a greater risk for stroke (RR: 1.40; 95% CI: 1.17–1.68), combined cardio-vascular disease 
(RR: 1.19; 95% CI: 1.09–1.30), and heart failure (RR: 1.30; 95% CI: 1.10–1.54) compared with 
those receiving chlorthalidone; treatment differences which were far more pronounced in 
African-Americans when compared with whites.42 Furthermore, the ALLHAT researchers 
reported a higher risk of stroke in African-American hypertensive patients treated with 
lisinopril as opposed to amlodipine (RR: 1.51; 95% CI: 1.22–1.86); an association which was not 
observed in non–African Americans (RR: 1.07; 95% CI: 0.89–1.28).42 Subsequent meta-analyses 
reiterate these findings, demonstrating no evident benefit from ACE inhibitors in achieving 
DBP goals for African-American hypertensive patients.48,49 Conversely, ACEi may offer 
substantial benefits for African-Americans with hypertensive renal disease; in the African-
American Study of Kidney Disease and Hypertension (AASK), ramipril slowed renal disease 
progression in African-Americans irrespective of whether proteinuria was present, more so 
than amlodipine or metoprolol.50 However, demographic differences with the UK (e.g., a large 
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South Asian population, population ‘ad-mixture’, first/second-generation immigrants as 
opposed to a population resident for two-three centuries, etc.), along with variations in 
vascular risk, diet and weight, restrict the utility of US data.  
 
The evidence for differential responses to antihypertensive drugs on the basis of ethnicity in 
the UK is more limited, with an analysis from 203 African, 132 South-Asian and 4368 white 
participants in the UK arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA) 
perhaps the most robust source of data.51 This sought to determine whether there were ethnic 
variations in response to mono-therapy using beta-blockers (atenolol) or calcium channel 
blockers (amlodipine), and then to add-on therapy with a thiazide diuretic 
(bendroflumethiazide) or ACEi (perindopril). The degree of blood pressure reduction achieved 
in black patients receiving atenolol mono-therapy was significantly lower when compared to 
white patients; South Asian patients achieved an intermediate treatment effect. Amlodipine 
mono-therapy resulted in similar blood pressure lowering effects across all three ethnic 
groups, as did the addition of bendroflumethiazide to atenolol. However, the addition of 
perindopril to amlodipine, resulted in statistically significant BP differences; white patients 
achieved a further 1.7 mmHg fall in SBP (95% CI: -2.8 to -0.7 mmHg), black patients exhibited a 
diminished response (SBP change: -0.8 mmHg; 95% CI: -2.5 to +4.2 mmHg) whilst South-Asians 
demonstrated a greater response (SBP change: -6.2 mmHg; 95% CI -10.2 to -2.2 mmHg).51  
 
The AIM-HY INFORM trial aims to optimize first and second-line anti-hypertensive therapies 
for the multi-ethnic population of the UK. In doing so, it will refine the ‘black vs white’ 
approach embodied in the current NICE guideline and further codify the treatment of 
hypertension. The systematic and robust trial data produced will also compare the value of 
self-defined ethnicity against genetically-defined ancestry and metabolomics, informing future 
studies in low and middle income countries, where the utilisation of existing, generic, drugs in 
a resource-efficient manner is imperative.  
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Figure 1: Trial Flow Chart 
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Table I: Trial objectives 
 
Primary objective 
 
- To determine whether the response to antihypertensive drugs differs on the basis of self defined ethnicity 
 
Secondary objectives 
 
- To determine if the response to antihypertensive drugs differs by: 
-  Ancestry Informative Markers  
-  Baseline metabolomics 
-  Baseline haemodynamics 
-  Genomics 
-  Detailed SDE (family tree extending to grandparents) of ethnicity background)  
- To compare detailed SDE with AIMs as a cause for the response to antihypertensive drugs  
- To determine the most effective mono- and dual-therapy for hypertension, and whether this varies by ethnicity 
- To determine whether metabolomics and haemodynamics differ by ethnicity 
- To test whether previously identified biomarkers (derived from other cohorts e.g. US) can predict drug response  
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Table II: Selection criteria  
 
Inclusion Criteria  
 
1. Able to give written informed consent 
2. Aged 18 to 65 years 
3. Self-defined ethnicity falling into one of three groups: 
-  White  
 (White British, White Irish, or any other white background) 
-  Black/Black British  
 (Black Caribbean, Black African, or any other black background) 
-  Asian/Asian British  
 (Asian Indian, Asian Pakistani, Asian Bangladeshi, or any other South Asian background) 
4. Hypertensive as defined by:  
 -  Mono-therapy  
  -  Treatment naïve patients:  
   Day-time average SBP ≥ 135 mmHg or DBP ≥ 85 mmHg,  
   Using ABPM or HBPM (validated device based on an average of 10 readings)  
  - Treated patients:  
   Day-time average SBP ≥ 135 mmHg or DBP ≥ 85 mmHg,  
   Using ABPM or HBPM (validated device based on an average of 10 readings), if: 
   Likely to achieve control on a study drug whilst being willing and able to complete 2-4 weeks wash out 
 -  Dual-therapy  
  - Treated (with 1-3 anti-hypertensive agents):  
   Day-time average SBP 135-200 mmHg and/or DBP 85-110 mmHg,  
   Using ABPM or HBPM (validated device based on an average of 10 readings) 
 
Exclusion Criteria  
 
a. Inability to identify with one of the pre-defined ethnic groups e.g., ad-mixed origin 
b. Pregnant or breastfeeding females 
c. Known or suspected secondary hypertension 
d. Significant sensitivity or contraindications to study medicines 
e. Concomitant lithium or variable dose NSAID use 
f. A requirement to take any of the study drugs continuously e.g. ACEi and heart failure 
g. Clinically significant hepatic impairment 
h. Clinically significant kidney impairment 
i. Concurrent clinical trial participation  
(systemically vasoactive medicines or drugs known to interact with the study medicines)  
j. Patients deemed unsuitable by the investigator on clinical grounds e.g. patients in atrial fibrillation (AF) 
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Table III: Selection criteria  
 
Mono-therapy  
 
A. 1-2 weeks of Amlodipine 5 mg od followed by 6-7 weeks of Amlodipine 10 mg od 
 
B. 1-2 weeks of Lisinopril 10 mg od followed by 6-7 weeks of Lisinopril 20 mg od  
 
C. Approximately 8 weeks of Chlorthalidone 25 mg od 
 
Dual-therapy:  
 
A. Approximately 8 weeks of Amlodipine 5 mg od and Lisinopril 20 mg od 
 
B. Approximately 8 weeks of Amlodipine 5 mg od and Chlorthalidone 25 mg od 
 
C. Approximately 8 weeks of Lisinopril 20 mg od and Chlorthalidone 25 mg od  
 
D. Approximately 8 weeks of Amiloride 10 mg od and Chlorthalidone 25 mg od 
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Table IV: Outcome Measures 
 
Primary outcome measure 
 
- Seated, automated, unattended, office SBP, measured approximately 8 weeks after each treatment 
 
Secondary outcome measures 
 
- All participants  
 - Seated automated, office DBP 
 - Detailed self defined ethnicity 
 - Core cardiovascular measurements 
  - Body composition assessment to determine lean and fat tissue mass 
  - Pulse wave analysis (carotid & femoral arteries) to derive pulse wave velocity, central (aortic) waveforms, and central blood pressure  
  - Echocardiography (including left ventricular mass and volume assessments) 
  - Dundee (three-minute) step test (baseline only) 
 
- Subgroups 
 - ABPM and/or HBPM 
 - Optional cardiovascular measurements 
  - Heart rate variability 
  - Regional arterial diameters 
  - CO and SV assessment (using a non-invasive, inert gas re-breathing technique)  
 
Tertiary outcome measures 
 
- Haemodynamic and genomic measures 
- Baseline demographics comparison 
- Urine drug screening (random sub-group sample)  
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